The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.
Conclusions: The choice of mepolizumab allows patients with severe eosinophilic asthma to achieve clinical improvement regardless of the history of previous treatment with omalizumab.Median[Q25,75]Group AGroup BCSEBaseline4[3,6]4[3,5]1 year 1[0,2] 1[0,1] 2 years 2[1,4] 1[0,3]ACT Baseline16[12,18]16[12,18]1 year22[20,24]23[21,24]2 years21[20,24]23[21,24]FEV1(L)Baseline1.7[1.3,2.3]1.8[1.4,2.4]1 year2[2.6,1.6]2.2[1.7,2.7]2 years2.1[1.5,2.4]2.3[1.7,2.7] (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Kallieri, M., Papaioannou, A. I., Zervas, E., Fouka, E., Porpodis, K., Hadji Mitrova, M., Tzortzaki, E., Makris, M., Ntakoula, M., Lyberopoulos, P., Dimakou, K., Koukidou, S., Ampelioti, S., Papaporfyriou, A., Katsoulis, K., Kipourou, M., Rovina, N., Anto Tags: Airway pharmacology and treatment Source Type: research
Eosinophils sub-types in patients with severe asthma treated with monoclonal antibodies.
Conclusions: The effect of monoclonal antibodies is different in the eosinophils sub-types. The eosinophils that remain in peripheral blood despite the use of mepolizumab seem to correspond to rEos with homeostatic functions. Omalizumab and dupilumab do not change the proportion of eosinophils subtypes but decrease IL3 receptor. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Cabrera-Lopez, C., Sanchez-Santos, A., Lemes-Catellano, A., Cazorla-Rivero, S., Gonzalez-Davila, E., Celli, B., Casanova-Macario, C. Tags: Airway pharmacology and treatment Source Type: research
Assessment of the impact of infection SARS-CoV-2 on the control and Lung function of patients with severe asthma
Conclusions: SARS-CoV-2 infection affected the control of baseline respiratory disease, with a decrease in the ACT and CARAT scores, but did not affect pulmonary function. In the literature there are not many studies on these changes, so studies should be done with a larger number of patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Cunha Craveiro, A. P., Gomes, M., Cunha Silva, J., Mendes, A., Pedro, M. E. Tags: Monitoring airway disease Source Type: research
A retrospective real-life study on the switch of biologics in severe asthma
Conclusions: Based on our retrospective criteria each biologic showed a high rate of success. OMA response was lower probably because of its first usage that limited the best eligibility based on personalized therapy. Response, despite "criteria label", should be evaluated "case-by-case". Switching aimed to reach a complete control on asthma symptoms/comorbidities and occurred mostly from anti-IgE to anti-IL-5/IL-5R/IL-4Rα and from anti IL-5/IL-5R to anti-IL-4Rα. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Garino, S., Guida, G., Riccardi, E., Carriero, V., Bertolini, F., Brusamento, M., Pizzimenti, S., Levra, S., Ricciardolo, F. L. M. Tags: Monitoring airway disease Source Type: research
"Head-to-head" comparison between biologics in severe asthma: a real-world study
Conclusions: Dupi-treated patients showed a lower T2 profile and the worst lung function. Response to biologics showed comparable data with literature, with some different evidence. "Head to head" comparison showed the superiority of a single biologic compaired to another with regard to specific traits. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Riccardi, E., Guida, G., Garino, S., Bertolini, F., Carriero, V., Brusamento, M., Pizzimenti, S., Levra, S., Ricciardolo, F. L. M. Tags: Monitoring airway disease Source Type: research
Clinical characteristics of responders and non-responders: experience following four years of Benralizumab therapy
Conclusion: Benralizumab responders have improved asthma control, reduction in exacerbations and OCS use that persists after four years of treatment. Non-responders had significantly higher rates of co-existing BPD, highlighting the importance of MDT team assessment. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Nuttall, A., Fyles, F., Joplin, H., Burhan, H., Watkins, L. Tags: Airway pharmacology and treatment Source Type: research
Biologics in allergic rhinitis
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):43-52. doi: 10.26355/eurrev_202310_34069.ABSTRACTThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biol...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2023 Category: Drugs & Pharmacology Authors: N Bayar Muluk C Cingi Source Type: research
Indication of Omalizumab for Chronic Urticaria Using the `Urticaria Control Test' Instead of `Urticaria Activity Score': Possible Impact for Health Systems
Actas Dermosifiliogr. 2023 Oct 21:S0001-7310(23)00838-4. doi: 10.1016/j.ad.2023.10.010. Online ahead of print.NO ABSTRACTPMID:37871896 | DOI:10.1016/j.ad.2023.10.010 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - October 23, 2023 Category: Dermatology Authors: J S ánchez L Alvarez J F L ópez Source Type: research
Biologics in allergic rhinitis
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):43-52. doi: 10.26355/eurrev_202310_34069.ABSTRACTThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biol...
Source: Pharmacological Reviews - October 23, 2023 Category: Drugs & Pharmacology Authors: N Bayar Muluk C Cingi Source Type: research
Biologics in allergic rhinitis
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):43-52. doi: 10.26355/eurrev_202310_34069.ABSTRACTThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biol...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2023 Category: Drugs & Pharmacology Authors: N Bayar Muluk C Cingi Source Type: research
Indication of Omalizumab for Chronic Urticaria Using the `Urticaria Control Test' Instead of `Urticaria Activity Score': Possible Impact for Health Systems
Actas Dermosifiliogr. 2023 Oct 21:S0001-7310(23)00838-4. doi: 10.1016/j.ad.2023.10.010. Online ahead of print.NO ABSTRACTPMID:37871896 | DOI:10.1016/j.ad.2023.10.010 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - October 23, 2023 Category: Dermatology Authors: J S ánchez L Alvarez J F L ópez Source Type: research
Biologics in allergic rhinitis
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):43-52. doi: 10.26355/eurrev_202310_34069.ABSTRACTThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biol...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2023 Category: Drugs & Pharmacology Authors: N Bayar Muluk C Cingi Source Type: research
Indication of Omalizumab for Chronic Urticaria Using the `Urticaria Control Test' Instead of `Urticaria Activity Score': Possible Impact for Health Systems
Actas Dermosifiliogr. 2023 Oct 21:S0001-7310(23)00838-4. doi: 10.1016/j.ad.2023.10.010. Online ahead of print.NO ABSTRACTPMID:37871896 | DOI:10.1016/j.ad.2023.10.010 (Source: Actas Dermo-Sifiliograficas)
Source: Actas Dermo-Sifiliograficas - October 23, 2023 Category: Dermatology Authors: J S ánchez L Alvarez J F L ópez Source Type: research
Biologics in allergic rhinitis
Eur Rev Med Pharmacol Sci. 2023 Oct;27(5 Suppl):43-52. doi: 10.26355/eurrev_202310_34069.ABSTRACTThis paper aims to review biologics in allergic rhinitis (AR). Biologic agents of Omalizumab, Dupilumab, Mepolizumab, Reslizumab, and Benralizumab are reviewed in detail. The search is performed in "Pubmed," "Google," Google Scholar" and EBSCO Academic Search Ultimate (EKUAL) database of Kırıkkale University Library from 2021 to 2000, and randomized and/or placebo-controlled studies, review papers, meta-analysis, and reports are taken into consideration. The search was performed with the keywords of "allergic rhinitis," "biol...
Source: European Review for Medical and Pharmacological Sciences - October 23, 2023 Category: Drugs & Pharmacology Authors: N Bayar Muluk C Cingi Source Type: research
